Literature DB >> 6883722

Determination of Gaucher's disease phenotypes with monoclonal antibody.

E I Ginns, F P Tegelaers, R Barneveld, H Galjaard, A J Reuser, R O Brady, J M Tager, J A Barranger.   

Abstract

Discrimination between the three clinical subtypes of Gaucher's disease based on the molecular forms of beta-glucocerebrosidase detected by monoclonal antibody is described. In normal fibroblast extracts, cross-reacting material (CRM) to human placental glucocerebrosidase is detected at Mr approximately equal to 63 000, 61 000 and 56 000. In Type 1 Gaucher's disease, the major fibroblast CRM has a Mr approximately equal to 56 000,, with less CRM seen at 61 000 and 56 000. Type 3 fibroblast extracts have a single CRM form at Mr approximately equal to 63 000. No CRM is found in Type 2 Gaucher's disease fibroblasts with monoclonal antiglucocerebrosidase antibody 8E4.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883722     DOI: 10.1016/0009-8981(83)90097-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

Authors:  J M Aerts; W E Donker-Koopman; S Brul; S Van Weely; M C Sa Miranda; J A Barranger; J M Tager; A W Schram
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

2.  Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.

Authors:  S Tsuji; B M Martin; J A Barranger; B K Stubblefield; M E LaMarca; E I Ginns
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease.

Authors:  E I Ginns; P V Choudary; S Tsuji; B Martin; B Stubblefield; J Sawyer; J Hozier; J A Barranger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

4.  Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in Escherichia coli.

Authors:  Juliana Branco Novo; Maria Leonor Sarno Oliveira; Geraldo Santana Magalhães; Ligia Morganti; Isaías Raw; Paulo Lee Ho
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

Review 5.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

Authors:  N Gupta; I M Oppenheim; E F Kauvar; N Tayebi; E Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-28       Impact factor: 3.039

6.  Glucocerebrosidase "processing" and gene expression in various forms of Gaucher disease.

Authors:  E Beutler; W Kuhl; J Sorge
Journal:  Am J Hum Genet       Date:  1985-11       Impact factor: 11.025

7.  Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies.

Authors:  R A Barneveld; W Keijzer; F P Tegelaers; E I Ginns; A Geurts van Kessel; R O Brady; J A Barranger; J M Tager; H Galjaard; A Westerveld; A J Reuser
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

8.  Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.

Authors:  D Fabbro; R J Desnick; G A Grabowski
Journal:  Am J Hum Genet       Date:  1987-01       Impact factor: 11.025

9.  Ultrastructural localization of glucocerebrosidase in cultured Gaucher's disease fibroblasts by immunocytochemistry.

Authors:  R Willemsen; J M van Dongen; E I Ginns; H J Sips; A W Schram; J M Tager; J A Barranger; A J Reuser
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

10.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

Authors:  G A Grabowski; T Dinur; K M Osiecki; J R Kruse; G Legler; S Gatt
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.